Michael Seaman

Michael Seaman, Ph.D.

Michael Seaman, Ph.D.

Principal Investigator
Seaman Laboratory

Assistant Professor of Medicine, Harvard Medical School

mseaman@bidmc.harvard.edu
T: 617-735-4449
F: 617-735-4540

Education

  • University of Washington, Seattle, WA, B.S., 1992 (Microbiology)
  • University of Texas Southwestern Medical Center, Dallas, TX, Ph.D., 2000 (Immunology)

Training

  • Research Fellow, Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Boston, MA, 2004 (Immunology)

Appointments

  • 1992-1994, Research Assistant I and II, Department of Immunobiology, Immunex Corporation, Seattle, WA
  • 2004-2007, Instructor in Medicine, Harvard Medical School, Boston, MA
  • 2007-2017, Assistant Professor of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
  • 2017- present, Associate Professor of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

Honors

  • 1996-1999, NRSA Predoctoral Trainee, NIH #5 T32 CA09082
  • 2000-2002, NRSA Fellow, Postdoctoral Training Program in AIDS Research (Dana-Farber Cancer Institute, NIH #5 T32 AI07386)
  • 2008, Network Citizenship Award, NIH HIV Vaccine Trials Network (HVTN)
  • 2012, Young/Early Career Investigator Award, Collaboration for AIDS Vaccine Development (CAVD)

Publications

  • Tartaglia LJ, Gupte S, Pastores KC, et al. Differential Outcomes following Optimization of Simian-Human Immunodeficiency Viruses from Clades AE, B, and C. J Virol. 2020;94(10):e01860-19. Published 2020 May 4. doi:10.1128/JVI.01860-19 [Article]

  • Silver ZA, Dickinson GM, Seaman MS, Desrosiers RC. A Highly Unusual V1 Region of Env in an Elite Controller of HIV Infection. J Virol. 2019 May 15;93(10). doi: 10.1128/JVI.00094-19. [Article]

  • Schoofs T, Barnes CO, Suh-Toma N, Golijanin J, Schommers P, Gruell H, West AP Jr, Bach F, Lee YE, Nogueira L, Georgiev IS, Bailer RT, Czartoski J, Mascola JR, Seaman MS, McElrath MJ, Doria-Rose NA, Klein F, Nussenzweig MC, Bjorkman PJ. Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. Immunity. 2019 Jun 18;50(6):1513-1529.e9. [Article]

  • Han Q, Jones JA, Nicely NI, Reed RK, Shen X, Mansouri K, Louder M, Trama AM, Alam SM, Edwards RJ, Bonsignori M, Tomaras GD, Korber B, Montefiori DC, Mascola JR, Seaman MS, Haynes BF, Saunders KO. Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations. Nat Commun. 2019 Jul 1;10(1):2898. [Article]

  • Kerwin BA, Bennett C, Brodsky Y, Clark R, Floyd JA, Gillespie A, Mayer BT, McClure M, Siska C, Seaman MS, Seaton KE, Shaver J, Tomaras GD, Yates NL, Ketchem RR. Framework mutations of the 10-1074 bnAb increase conformational stability, manufacturability and stability while preserving full neutralization activity. J Pharm Sci. 2019 Jul 23;. doi: 10.1016/j.xphs.2019.07.009. [Epub ahead of print]. [Article]

  • Bricault CA, Yusim K, Seaman MS, Yoon H, Theiler J, Giorgi EE, Wagh K, Theiler M, Hraber P, Macke JP, Kreider EF, Learn GH, Hahn BH, Scheid JF, Kovacs JM, Shields JL, Lavine CL, Ghantous F, Rist M, Bayne MG, Neubauer GH, McMahan K, Peng H, Chéneau C, Jones JJ, Zeng J, Ochsenbauer C, Nkolola JP, Stephenson KE, Chen B, Gnanakaran S, Bonsignori M, Williams LD, Haynes BF, Doria-Rose N, Mascola JR, Montefiori DC, Barouch DH*, Korber B*. HIV-1 neutralizing antibody signatures and application to epitope-targeted vaccine design. Cell Host Microbe 2019; 25:59-72. [Article]

  • Hartweger H, McGuire AT, Horning M, Taylor JJ, Dosenovic P, Yost D, Gazumyan A, Seaman MS, Stamatatos L, Jankovic M, Nussenzweig MC. HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells. J Exp Med. 2019 Jun 3;216(6):1301-1310. [Article]

  • Escolano A, Gristick HB, Abernathy ME, Merkenschlager J, Gautam R, Oliveira TY, Pai J, West AP Jr, Barnes CO, Cohen AA, Wang H, Golijanin J, Yost D, Keeffe JR, Wang Z, Zhao P, Yao KH, Bauer J, Nogueira L, Gao H, Voll AV, Montefiori DC, Seaman MS, Gazumyan A, Silva M, McGuire AT, Stamatatos L, Irvine DJ, Wells L, Martin MA, Bjorkman PJ, Nussenzweig MC. Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques. Nature. 2019 Jun;570(7762):468-473.

  • Asbach B, Kibler KV, Köstler J, Perdiguero B, Yates NL, Stanfield-Oakley S, Tomaras GD, Kao SF, Foulds KE, Roederer M, Seaman MS, Montefiori DC, Parks R, Ferrari G, Forthal DN, Phogat S, Tartaglia J, Barnett SW, Self SG, Gottardo R, Cristillo AD, Weiss DE, Galmin L, Ding S, Heeney JL, Esteban M, Jacobs BL, Pantaleo G, Wagner R. Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost. J Virol. 2019 Feb 1;93(3). [Article]

  • Kibler KV, Asbach B, Perdiguero B, García-Arriaza J, Yates NL, Parks R, Stanfield-Oakley S, Ferrari G, Montefiori DC, Tomaras GD, Roederer M, Foulds KE, Forthal DN, Seaman MS, Self S, Gottardo R, Phogat S, Tartaglia J, Barnett S, Cristillo AD, Weiss D, Galmin L, Ding S, Heeney JL, Esteban M, Wagner R, Pantaleo G, Jacobs BL. Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC. J Virol. 2019 Feb 1;93(3). [Article]